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The highly invasive nature of glioblastoma imposes poor prospects for patient survival.
Molecular evidence indicates glioblastoma cells undergo an intriguing expansion of
phenotypic properties to include neuron-like signaling using excitable membrane ion
channels and synaptic proteins, augmenting survival and motility. Neurotransmitter
receptors, membrane signaling, excitatory receptors, and Ca2+ responses are
important candidates for the design of customized treatments for cancers within the
heterogeneous central nervous system. Relatively few published studies of glioblastoma
multiforme (GBM) have evaluated pharmacological agents targeted to signaling pathways
in limiting cancer cell motility. Transcriptomic analyses here identified classes of ion
channels, ionotropic receptors, and synaptic proteins that are enriched in human
glioblastoma biopsy samples. The pattern of GBM-enriched gene expression points to
a major role for glutamate signaling. However, the predominant role of AMPA receptors in
fast excitatory signaling throughout the central nervous system raises a challenge on how
to target inhibitors selectively to cancer cells while maintaining tolerability. This review
critically evaluates a panel of ligand- and voltage-gated ion channels and synaptic proteins
upregulated in GBM, and the evidence for their potential roles in the pathological disease
progress. Evidence suggests combinations of therapies could be more effective than
single agents alone. Natural plant products used in traditional medicines for the treatment
of glioblastoma contain flavonoids, terpenoids, polyphenols, epigallocatechin gallate,
quinones, and saponins, which might serendipitously include agents that modulate
some classes of signaling compounds highlighted in this review. New therapeutic
strategies are likely to exploit evidence-based combinations of selected agents, each at
a low dose, to create new cancer cell-specific therapeutics.
Keywords: ionotropic glutamate receptor, synaptic protein expression, transcriptomic, ion channels, traditional
herbal medicines, aquaporin, glioblastomain.org March 2020 | Volume 11 | Article 3581
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SEVERELY LIMITS PATIENT SURVIVAL
The prospects for survival of patients diagnosed with glioblastoma
are poor, even with the most powerful therapies, largely because of
the highly invasive nature of the cancer. After diagnosis, average
survival expectancy ranges from a few months to less than 2 years,
depending on cancer subtype and treatment strategy (Stupp et al.,
2005). As reviewed recently, glioblastoma is divided into primary
GBM, constituting 80% of cases with a mean age of onset at 62
years, and secondary GBM progressing from lower grade
astrocytomas or oligodendrogliomas with a mean age of onset of
45 years (Ghosh et al., 2018). Glioblastomamultiforme is designated
as Grade IV by theWorld Health Organization, the most malignant
type of brain tumor. Molecular markers that have been defined for
GBM include DNA repair and methylation enzymes, epidermal
growth factor receptor, proto-oncogenes, and tumor suppressor
genes (Ghosh et al., 2018). Current treatments for GBM depend on
a combination of surgical resection, radiation therapy and
chemotherapy, but even with this multi-pronged approach,
median survival time is only 14.6 months (Ghosh et al., 2018).
In historical records, the first intracranial procedure in 1884
to remove a glial tumor was attributed to Bennett and Godlee
(Walker et al., 1976). Surgical resection can remove most of a
tumor bulk, but the problem is that a subset of GBM cells at the
time of treatment will have already spread a substantial distance
beyond the visible boundary of the main mass. Postmortem
analyses of sectioned whole brains from untreated GBM patients
revealed that in none of the 15 cases studied did the computer-
tomography defined area capture the full extent of the neoplasm,
and in three cases, infiltration extended 3.5 to 5 cm beyond the
observed electron-dense boundaries of the tumors (Burger et al.,
1988). Conventional radiological evaluations frequently
underestimate the full area over which an invasive glioma has
extended (Claes et al., 2007). In the late 1970s, addition of
radiotherapy after surgery was shown to further improve GBM
patient survival, and has since been refined progressively to
optimize focused applications (Mann et al., 2017). Radiation
damage to DNA acts to decrease cell proliferation, but falls short
of being curative as a result of the invasive nature of GBM, as well
as radiation-induced necrosis, neuronal damage, and the
insensitivity of some GBM subtypes to radiation treatment.
Adjuvant chemotherapy was found to further improve survival.
In 2005, a Phase 3 clinical trial conducted by the European
Organization for Research and Treatment of Cancer (EORTC)
26981-22981/National Cancer Institute of Canada Clinical Trials
Group (NCIC CTG) showed significantly better overall survival
when patients were treated with temozolomide in combination
with radiotherapy and maximal surgical resection (Stupp et al.,
2005). However, recurrence remains a serious problem, as GBM
cells escape resection by early migration, and show inherent or
acquired resistance to chemo- and radio therapy treatments
(Ghosh et al., 2018). More work is needed to understand the
mechanisms of motility, to define new intervention strategies for
this devastating disease, and potentially to aim treatments to
specific subtypes of GBM.Frontiers in Pharmacology | www.frontiersin.org 2GBM arises throughout the brain most frequently in the cerebral
hemispheres, particularly in frontal lobes or both frontal and
temporal lobes, whereas it is relatively rare in cerebellum (Iacob
and Dinca, 2009). Categories of glioblastoma traditionally were
defined based on histology; recently a systematic correlation of
phenotypes with molecular markers identified diagnostic indicators
of the major subtypes (Louis et al., 2016; Verhaak, 2016). The
molecular markers themselves are not necessarily key drivers of
glioblastoma pathology, but their usefulness in defining subtypes is
expected to allow tailoring of treatment aggressiveness to optimize
patient outcomes (Verhaak, 2016). Frequently altered pathways in
cancers involve tyrosine and serine/threonine kinases and relevant
receptors, including the epidermal growth factor receptor (EGFR),
which alter the regulation of Ras oncogenes overexpressed in
glioblastoma (Cancer Genome Atlas Research, 2008).
Downstream cascades of kinases include the mitogen-activated
protein kinase family that are associated with an array of
outcomes including proliferation, invasion, and chemotherapy
resistance. We suggest that additional contributions from
neurotransmitters, membrane signaling, excitatory receptors, and
Ca2+ responses could be similarly important, and might offer
opportunities for customized treatment of cancer cells within the
heterogeneous cell populations of the central nervous system by
combinations of agents at subtoxic doses.
Limiting cell migration is a compelling goal in the broad
cancer field. Tools for managing the invasive spread of cancer
cells in general through the body are essential, given that
metastasis is a major cause of cancer-related deaths (Welch
and Hurst, 2019). In GBM, the cancer rarely metastasizes
outside the central nervous system, yet within the brain the
highly invasive properties of these cells constitute a major
challenge for effective treatment. Controlling GBM spread
using inhibitors of cell migration and invasion would
constitute a powerful adjunct therapy that could be applied in
parallel with other procedures aimed at direct eradication of
primary tumors. This review critically evaluates classes of ligand-
and voltage ion channels and synaptic proteins as new targets for
experimental therapies in GBM, and integrates cross-disciplinary
evidence for their potential roles in the pathological features
of glioblastoma.PHARMACOLOGICAL TARGETS FOR
CANCER TREATMENT
The majority of published work in the drug discovery field for
cancers including GBM has focused on cell death and reduced
proliferation as the primary outcomes of interest for therapeutics.
While these candidate agents would have desired effects of killing
cancer cells, non-selective toxicity, side-effects, and efficacy in vivo
remain constraints on effective drug development. Alkylating agents
that modify DNA structure have been shown to improve patient
survival by driving apoptosis of the cancer cells, but concurrent
activity on non-cancerous cells creates side effects which limit
tolerable doses. Alkylating agents for GBM include
chloroethylating drugs such as carmustine and lomustine, andMarch 2020 | Volume 11 | Article 358
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comparatively lower toxicity, has in combination with
radiotherapy become a standard of care for GBM patients in
countries that can afford the high cost of this chemotherapeutic
agent (Lonardi et al., 2005). A second tier of cytotoxic agents for
non-responsive GBM cases includes carboplatin, etoposide,
oxaliplatin, and irinotecan. These agents also alter DNA to reduce
cell proliferation, with greatest effects exerted on populations of
rapidly dividing cells such as cancers. Anti-angiogenic agents and
antibodies against EGFR and other tyrosine kinase receptors also
have been of interest for new experimental chemotherapy strategies
(Iacob and Dinca, 2009). A major gap in knowledge in this field is
how to constrain GBM cell motility while treatments of the primary
tumor masses are in progress, preventing the escape that leads to
recurrence. As summarized in this review, the discovery of
pharmacological tools to intervene in processes of cell migration
and invasion in GBM is a promising area of work, possibly utilizing
traditional medicinal herbs as one source of novel agents, but this
area remains largely unexplored to date. As an indicative survey, of
more than 38,000 papers listed in the National Institutes of Health
PubMed database that were identified as relevant to glioblastoma as
of Nov 2019, 18% identified use of an inhibitor, 26% were linked to
proliferation, and 11% considered effects on motility (Figure 1).
Less than 4% of published studies in glioblastoma evaluated
candidate therapeutics as tools for limiting cancer cell motility.
Approximately 2% of the papers published evaluated the effects of
inhibitors on both cell survival and motility.
Evidence suggests combinations of therapies could bemore effective
than single agents alone. For example, a Chinese traditional medicinal
extract known as Compound Kushing Injection has been fractionated,
chemically defined, and evaluated for dose-dependent activities in a
broad array of cancer cell types measured by changes in rates of
migration, cell survival, proliferation, and gene expression
(Nourmohammadi et al., 2019). The interesting conclusions drawn
in this work were that no single compound in the Compound Kushing
Injection mixture accounted for the full therapeutic effect of the whole
extract; combinations of agents were required to reconstitute the
beneficial activity, and the most effective combinations of
compounds depended on the cancer cell type. Combined block of
glioma cells with 5-nitro-2-(3-phenylpropylamino)-benzoate (a non-
specific chloride channel blocker), covalently linked to temozolomide
(an oral chemotherapeutic drug for glioblastoma) suppressed glioma
cell proliferation, migration, and invasion (Park et al., 2016).
Temozolomide modifies DNA or RNA at guanine and adenine
bases by addition of methyl groups (Lee, 2016); however, a
substantial proportion of tumors are insensitive to temozolamide due
to expression of methyltransferase genes.
Limitations of current therapies highlight the need for new drugs
that induce fewer side effects and can lead to a more favorable
prognosis. While the combination of radiotherapy and
temozolomide is a principal treatment strategy, a rising concern is
that radiation exposure at therapeutic levels can alter gene
expression and signaling to promote a highly invasive phenotype
in the surviving glioblastoma cells (Birch et al., 2018). PromisingFrontiers in Pharmacology | www.frontiersin.org 3results have indicated that a blocker of a key kinase (which regulates
cytoskeletal contractility at the leading edges of glioblastoma
tumors) could be co-administered to suppress the recurrence of
the invasive cells after radiotherapy, with potential promise for
extending patient survival time and reducing the neurological
impairment associated with the disease (Birch et al., 2018). A
major active ingredient of the herbal medicinal plant ginseng
(ginsenoside Rg3), has additive anti-tumor and anti-angiogenic
effects when applied in combination with temozolomide (Sun
et al., 2016b). Epigallocatechin gallate from green tea synergizes
with temozolomide to inhibit viability, migration, and drug
resistance of glioma stem-like cells isolated from the U87 line
(Zhang et al., 2015). The anti-invasive activity of a medicinal
herbal extract from olive (Olea) leaf on glioblastoma stem cells
derived from human primary tumors was increased when given in
combination with bevacuazimab (Tezcan et al., 2017a). Further
work seems likely to demonstrate that the most effective clinical
strategies will include co-administration of multiple agents, targeted
to subtype-specific panels of factors in glioblastoma, to enhance the
successful outcomes of interventions.A
B
FIGURE 1 | Illustration of a sample distribution of published glioblastoma
studies suggesting less than 3% combine three themes (inhibitor,
proliferation, motility). Venn diagram (A) summarizing the numbers of
published articles on glioblastoma, with key words linked to inhibition,
migration and growth, as of November 2019 based on a search of the NIH
PubMed database, with search strings as defined in the table (B).March 2020 | Volume 11 | Article 358
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GLIOBLASTOMAL PROGRESSION
High motility, heterogeneity of cell types within the cancer
clusters, as well as the ability of the glioblastoma cells to
transition between proliferative and non-proliferative phases
make these cancers difficult to treat, and complicate the
accurate diagnoses of tumor types based on small biopsies
(Scherer, 1940; Singh et al., 2004; Behnan et al., 2019).
Migration pathways of glioblastoma through the human brain,
described by Scherer (1940) and confirmed in rodents with
human tumor cell implants (Laws et al., 1993), suggest a
predominant pattern of reliance on myelinated tracts such as
corpus callosum, basement membranes of blood vessels, pial
surfaces, and subependymal layers surrounding the ventricles as
routes for invasion. Insights from Scherer's work further
indicated that interactions with the brain tissue environment
were an important part of glioblastoma progression, a concept
highly relevant to current discoveries.
Surprising capacities for membrane signaling in glioblastoma
are reminiscent of properties characteristic of excitable cells, and
appear to be important for disease progression (Soroceanu et al.,
1999; Catacuzzeno et al., 2011; Molenaar, 2011; Wong et al.,
2017; Venkataramani et al., 2019; Venkatesh et al., 2019).
Although glioblastoma cells have been thought to arise from
glia in the CNS, molecular evidence indicates they originate from
stem cell precursors (Emlet et al., 2014), and undergo an
intriguing expansion of phenotypic properties to include
neuron-like signaling, which has been proposed to augment
glioblastoma cell survival and motility (Venkataramani et al.,
2019). As analyzed here, a select set of excitable membrane ion
channels and synaptic proteins (usually assumed to be the
province of cells such as neurons, not glia) are upregulated in
glioblastoma. This unusual portfolio of signaling proteins could
endow glioblastoma cells with functional capabilities that aid
their robust persistence and merit investigation as targets for new
therapeutics, though the signaling protein contributions to the
underlying pathological mechanisms are yet to be fully defined.
Glutamate, the main excitatory neurotransmitter in the
central nervous system, in early brain development promotes
the proliferation of neuronal progenitor cells, but interestingly
also has been found to enhance proliferation and migration in
glioblastoma cells (Lyons et al., 2007; Corsi et al., 2019).
Glutamate responses associated with glioblastoma are more
than excitotoxicity mechanisms to kill neurons and create
space for tumor growth (Sontheimer, 2008); the process is
an integral part of bidirectional communication between
neurons and glioblastoma cell networks (Robert and
Sontheimer, 2014; Ribeiro et al., 2017; Corsi et al., 2019).
Excitation of AMPA-activated classes of ionotropic glutamate
receptors (GluA1 to 4) augments the cell migration and
proliferation of human glioblastoma cells (Ishiuchi et al.,
2002), mediated in part by Ca2+-dependent activation of a
survival factor Akt kinase, as confirmed in surgical samples
and in glioblastoma cell lines (Ishiuchi et al., 2007).
Pathological tumor cells are not unique among non-neuronalFrontiers in Pharmacology | www.frontiersin.org 4brain cells in being responsive to glutamate; immature glia also
show sensitivity. In oligodendrocyte precursor cells, functional
synapses marked by fast depolarizing currents were measured in
response to voltage- and calcium-dependent release of glutamate
from pyramidal neurons in hippocampal slice preparations
(Bergles et al., 2000). During oligodendrocyte maturation,
signaling from axons is proposed to coordinate the process of
myelination. In human glioblastoma, synapses from neurons
onto glioblastoma cell processes were observed by electron
microscopy in resected tumor samples, complete with hallmark
structures including presynaptic docked vesicles, synaptic clefts,
and postsynaptic densities carrying AMPA receptors, confirmed
by molecular markers and electrophysiological recordings
(Venkataramani et al., 2019). Prior work had showed
glutamate-induced Ca2+ signals and suggested the occurrence
of action potentials in some dissociated cells cultured from
glioma samples (Labrakakis et al., 1998), though cell types in
the mixed sample were not precisely identified. Postsynaptic
responses characterized in identified glioblastoma depend
directly on the activity of surrounding neurons and seem
focused on increasing intracellular Ca2+; no action potentials
were observed in more than 300 tumor cells recorded
(Venkataramani et al., 2019). Signals driven by synaptic input
spread through the gap-junction linked network of glioma cells
to promote proliferation, and reciprocally drive hyperexcitability
of neurons in the glioma microenvironment, further boosting
glioblastoma synaptic input and amplifying the problem
(Venkatesh et al., 2019). We propose that analysis of a
transcriptomic database with a focus on classes of ion
channels, ionotropic receptors, and synaptic proteins that are
enriched in human glioblastoma biopsy samples, offers a timely
opportunity to generate predictive hypotheses for further testing
the possible functional roles of these signaling proteins in
glioblastoma progression.
Quantitative data on transcript levels measured from biopsied
samples from human glioblastoma multiforme (GBM) patients,
available in the Human Protein Atlas, were queried here to
compare the patterns of gene expression of an array of excitable
membrane signaling proteins for GBM patients with the
likelihood of their survival of at 3 years after diagnosis (Uhlen
et al., 2005; Uhlen et al., 2017). Table 1 provides a summary of
compiled data for the classes of ionotropic receptors, ion
channels, and synaptic proteins that showed distinct
upregulation in measured transcript levels in GBM patients.
Transcriptomic data were based on analyses of biopsied
samples from 153 patients diagnosed with GBM (54 female
and 99 male). At the time of the data collection, 123 patients
were deceased. Transcript levels were quantified as ‘Fragments
per kilobase of transcript per million fragments mapped'
(FPKM). The percent survival at 3 years is calculated from
deceased patients whose samples showed transcript levels for a
given signaling protein greater than the median value across the
GBM group; these values ranged from 3% to 14%, depending on
the gene. Several genes were significant as negative prognostic
indicators of survival when upregulated, including the small-
conductance Ca2+-activated K channel (KCa3.1), synaptotagminMarch 2020 | Volume 11 | Article 358
Yool and Ramesh Combined Targets for Glioblastoma TherapyTABLE 1 | Summary of ion channels and synaptic proteins showing enriched transcript levels (FPKM, fragments per kilobase of transcript per million fragments
mapped) in human glioblastoma biopsy samples, analyzed using TGCA RNAseq (n=153; Human Protein Atlas database); and percent survival at 3 years for patients








GRIA1 (GluA1, GLUR1, GLURA) ionotropic AMPA type 1 1 7.5 7
GRIA2 (GluA2, GLUR2, GLURB) ionotropic AMPA type 2 1 5.6 11
GRIA3 (GluA3, GLUR3, GLURC, MRX94) ionotropic AMPA type 3 1 8.5 10
GRID2 (GluD2, GluR-delta-2) ionotropic delta type 2 1 0.9 13
GRIK4 (GluK4, GRIK, KA1) ionotropic kainate type 4 1 3.05 13
>GRIA4 (GluA4, GLUR4, GLURD) ionotropic AMPA type 4 0 4.7 14
GRID1 (GluD1, KIAA1220) ionotropic delta type 1 0 3.4 7
GRIK1 (GluK1, GLUR5) ionotropic kainate type 1 0.25 3.2 7
GRIK2 (GluK2, GLUR6, MRT6) ionotropic kainate type 2 0.5 2.8 13
GRIK3 (GluK3, GLUR7) ionotropic kainate type 3 0 11 9
GRIK5 (GluK5, GRIK2, KA2) ionotropic kainate type 5 0 14.9 14
Gamma-aminobutyric acid (GABA) receptors
GABRA1 (EJM5) GABA- A alpha1 1 0.3 12
GABRG1 GABA-A gamma1 0.5 0.2 11
GABRB1 GABA-A beta1 0.25 0.5 5
GABRA2 GABA-A alpha2 0 0.4 6
GABRG2 GABA-A gamma2 0 0.4 11
Nicotinic cholinergic receptors
CHRNA1 (CHRNA) Cholinergic nicotinic alpha 1 1 0.9 6
CHRNA9 (NACHRA9) Cholinergic nicotinic alpha 9 0 1.4 12
CHRNB2 Cholinergic nicotinic beta 2 0 1.3 3
Calcium voltage-gated channels
CACNG3 voltage-gated Ca2+ channel gamma 3, brain 1 0.2 12
CACNG8 voltage-gated Ca2+ channel gamma 8, brain 1 1.1 8
CACNG5 voltage-gated Ca2+ channel gamma 5 0.25 0.1 6
CACNG7 voltage-gated Ca2+ channel gamma 7 0 27.9 12
Potassium voltage-gated and calcium-activated channels
KCNA2 (HK4, Kv1.2) voltage-gated K+ channel subfamily A 2, brain 1 1.0 14
KCNC1 (Kv3.1) voltage-gated K+ channel subfamily C, brain 1 0.9 5
KCND2 (KIAA1044, Kv4.2, RK5) voltage-gated K+ channel subfamily D 2, brain 1 4.3 12
KCNJ10 (Kir1.2, Kir4.1) voltage-gated K+ channel subfamily J 10, high in brain,
moderate in kidney
1 22.8 10
KCNJ9 (GIRK3, Kir3.3) Gprot activ inward rectifier K+ channel subfamily J 9, brain 1 1.7 7
KCNN3 (hSK3, KCa2.3, SKCA3) Ca2+-activated K+ channel subfamily N 3, brain 1 4.3 8
KCNQ2 (BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2) voltage-gated K+ channel subfamily Q 2, M channel, brain 1 7.2 7
KCNN2 (hSK2, KCa2.2) Ca2+-activated K+ channel subfamily N 2 0.25 2.6 11
KCNJ4 (HIR, hIRK2, HRK1, IRK3, Kir2.3) voltage-gated K+ channel subfamily J 4 0 1.3 12
KCNN4 (hIKCa1, hKCa4, hSK4, IK, KCa3.1) Ca2+-activated K+ channel subfamily N 4 (not GBM enriched) 0.5 0.9 8 *
Sodium voltage-gated channels
SCN2A (HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2) voltage-gated Na+ channel alpha 2, brain 1 1.1 7
SCN1A (FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI) voltage-gated Na+ channel alpha 1 0 1.6 13
SCN3A (Nav1.3) voltage-gated Na+ channel alpha 3 0.5 2.3 11
SCN3B (HSA243396) voltage-gated Na+ channel beta 3 0 1.3 6
Synaptic proteins
NSG2 (CALY3, HMP19, Nsg2) Neuronal vesicle trafficking associated 2 1 4.0 10
SNAP25 (bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9,
SNAP, SNAP-25)
Synaptosome associated protein 25 1 14.4 12
SNAP91 (AP180, CALM, KIAA0656) Synaptosome associated protein 91 1 1.3 9
SV2A (KIAA0736, SV2) Synaptic vesicle glycoprotein 2A 1 26.5 7
SYN1 Synapsin I 1 5.9 9
SYNPR (MGC26651, SPO) Synaptoporin 1 0.4 9
SYP (MRX96) Synaptophysin 1 10.3 6
SYT5 Synaptotagmin 5 1 1.2 11 *
SYT11 (DKFZp781D015, KIAA0080, MGC10881, MGC17226) Synaptotagmin 11 1 115 10
STX1B (STX1B1, STX1B2) Syntaxin 1B 0.75 3.9 10
(Continued)Frontiers in Pharmacology | www.frontiersin.org M5 arch 2020 | Volume 11 | Article 358
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exchanger NHE1 (though upregulation of this transporter was
seen in multiple types of cancers, not selectively in GBM).
Among the classes of ionotropic glutamate receptors enriched
in GBM patients (Table 1), transcript levels were high for the
AMPA-activated classes GluA1, GluA2, and GluA3, and the
kainate-activated class GluK5. Ionotropic receptors for GABA
and acetylcholine were enriched in GBM, but were not expressed
at levels as high as those seen for glutamate receptors. Analyses of
gene expression for the voltage-gated ion channel family showed
expression of CaV and NaV channels, as well as multiple types of K
+
channels. The highest levels of ion channel transcripts were seen for
the inward rectifier K+ channel Kir4.1, and were appreciable as well
for voltage-gated Kv4.2 and Kv7.2, and Ca2+-activated KCa2.3
channel classes. High levels of synaptic proteins were seen for
synaptosome-associated protein SNAP25, synaptic vesicle
glycoprotein, synapsin, synaptophysin, and synaptotagmins. Other
channels with higher levels of expression in GBM include
Aquaporins 1 and 4, the acid-sensing channel ASIC1, cyclic
nucleotide gated channel CNG3, and the chloride channel ClC3.
Though downregulation of expression of other genes in GBM also
could contribute to pathological features of the disease, work here
has focused on the genes showing upregulation of transcript levels,
based on the proposed goal of finding potential therapeutic targets
for novel inhibitory agents.TRANSCRIPTOMIC ANALYSES OF ION
CHANNEL GENES SELECTIVELY
ENRICHED IN GLIOBLASTOMA
Transcriptomic data from RNAseq analysis of human
glioblastoma samples (Human Protein Database) were further
analyzed by banding data into pooled subsets based on patient
survival duration, for intervals ranging from 0–3 months up to
more than 3 years, and calculating the transcript levels (median
FPKM values), depicted as a heat map (Figure 2). The negative
prognostic indicators NHE1 and Cx26 as expected showed aFrontiers in Pharmacology | www.frontiersin.org 6general pattern in which GBM patients with the highest levels of
transcript expression showed the shortest average survival times.
A similar pattern might be suggested by data for the voltage gated
Ca2+ channel, inward rectifier K+ channels, and Ca2+-activated
K+ channel classes shown. No distinct correlation between
survival and transcript level was evident in this analysis for
AQP1 and ClC3 channels, both identified previously as targets of
interest in pathological mechanisms of glioblastoma progression
(McCoy and Sontheimer, 2007; Cuddapah and Sontheimer,
2010; El Hindy et al., 2013). However, this link between
expression and survival is based on small biopsies of
heterogeneous tumor masses, and does not rule out potential
impacts for any of the channels or synaptic proteins that are
enriched in GBM. Signaling molecules often have overlapping
functions; thus, analyses that consider sets of related channels
within a class, rather than a specific individual channel, might
potentially be more meaningful predictors of survival outcomes
(see further discussion and Figure 4 below).GLUTAMATE RECEPTORS ENRICHED IN
GLIOBLASTOMA
Neurons in the central nervous system express diverse classes of
direct ligand-gated ion channels that are activated by changes in
membrane voltage, by the binding of intracellular ligands such as
Ca2+ and cyclic nucleotides, by the binding of extracellular ligands
such as neurotransmitters, or a combination. Glioblastoma cells
express a subset of receptors and channels which are associated with
excitable cells, and are of substantial interest for their potential roles
in signaling pathways that promote the aggressive and lethal
properties of the glioblastoma tumor. Of the direct ligand gated
channels, the highest transcript levels were for glutamate receptor
genes, with comparatively low levels seen for GABAA and nicotinic
acetylcholine receptors (Table 1).
Glutamate is the major excitatory neurotransmitter in the
brain and spinal cord, released from presynaptic terminals in







SYN2 (SYNII, SYNIIa, SYNIIb) Synapsin II 0 2.3 13
SYT6 Synaptotagmin 6 0 1.4 11
Other channels and transporters
AQP1 Aquaporin 1 1 240 12
AQP4 (MIWC) Aquaporin 4 1 180 9
BEST1 Bestrophin 3 Ca2+-activated chloride channel 1 1.7 9
ASIC1 (ACCN2, BNaC2, hBNaC2) Acid sensing ion channel subunit 1 0 10.4 7
CNGA3 (ACHM2, CCNC1, CCNCa, CNCG3, CNG3) Cyclic nucleotide gated channel alpha 3 0.5 5.3 8
GJB2 (Cx26) Gap junction protein beta 2 0.25 2.2 5 *
HCN2 (BCNG-2, BCNG2, HAC-1) Hyperpolarization activated cyclic nucleotide gated K+ and Na+
channel 2
0 6.3 10
SLC9A1 (APNH, NHE1, PPP1R143) Solute carrier family 9 member A1 (not GBM enriched) 1 6.5 6 *
CLCN3 (ClC3) Chloride voltage-gated channel (not GBM enriched) 0.5 19.0 13March 2020 | Volume 11 | A(*) indicates a confirmed unfavorable prognostic indicator in glioblastoma. Highlighted rows (yellow) indicate high scores for pathological evidence (1/1), supported by RNA, protein and
histological data.rticle 358
Yool and Ramesh Combined Targets for Glioblastoma Therapyvoltage-gated Ca2+ channels, and detected at postsynaptic
glutamate receptors, resulting in an excitatory change in
membrane potential. As reviewed by Traynelis and colleagues
(2010), direct ligand-gated glutamate receptors are cation-
permeable channels built as tetramers of subunits, and have been
subdivided by selective agonist sensitivities into the N-methyl-D-
aspartate (NMDA) and the non-NMDA classes (AMPA, alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, and
kainate), categories which align with genetic classifications based
on amino acid sequence homology. Transcripts enriched in
glioblastoma RNA seq data include receptors in the non-NMDAFrontiers in Pharmacology | www.frontiersin.org 7group activated by the agonist AMPA (GluA1 to -4) and by kainate
(GluK1 to -5).
A key determinant of ionic permeability of AMPA and
kainate receptors is the type of amino acid located in the
second transmembrane domain. In GluA2, the residue is either
glutamine (in the unedited form) yielding a receptor which
conducts Ca2+ as well as monovalent cations, or arginine (in
the edited form) which confers low Ca2+ permeability (Hume
et al., 1991; Verdoorn et al., 1991). Co-assembly of edited GluA2
with GluA1, 3 or 4 subunits prevents Ca2+ entry through the
receptor channel. In neurons, the efficiency of editing is high andFIGURE 2 | Correlation between relative expression levels of key genes and patient survival. Heat maps summarizing the quantitative median levels of transcripts
(FPMK, color bars) for 12 genes, for results banded into bins based on durations of patient survival. Results were calculated from TCGA data available in the Human
Protein Atlas. Asterisks indicate relative prognostic values: *** increased transcript expression is an unfavorable prognostic marker in GBM; ** transcript levels are
selectively enriched in GBM; * transcript levels are enhanced in cancers.March 2020 | Volume 11 | Article 358
Yool and Ramesh Combined Targets for Glioblastoma Therapythus the Ca2+ permeability of the majority of AMPA receptors is
negligible; however, in malignant brain tumors, the editing
efficiency is substantially reduced (Maas et al., 2001). Similarly
in pediatric glioblastomas, only 50 to 70% of the GluA2 RNA is
edited (Venkatesh et al., 2019), likely augmenting the Ca2+




Voltage-gated Ca2+ (CaV) channels are involved in diverse functions,
including regulating the entry of Ca2+ to control the release of
neurotransmitters and hormones. CaV channels are composed of a
number of subunits encoded by separate genes; the largest alpha-1
subunit forms the ion pore, and is associated with alpha-2, beta,
gamma and delta auxiliary subunits that modulate functional
properties. The Ca2+ channel-related genes showing transcript
levels enriched in glioblastoma (Table 1) were CaV gamma3, -7,
and -8. CaV alpha subunits were not represented in the GBM-
enriched category, perhaps hinting at a role for gammas other than
voltage-gated Ca2+ entry. As reviewed by Snutch and colleagues
(2000-2013), there are eight types of CaV g subunits. One of the first to
be discovered was stargazin (classified as g2), named after the
Stargazer mouse strain which is prone to absence seizures caused
by a mutation in the gamma2 gene. It is intriguing to note that
gamma subunits g3, g7, and g8 are expressed in brain and have been
found to serve as transmembrane AMPA receptor regulatory
proteins, known as TARPs (Tomita et al., 2003; Yamazaki et al.,
2010). TARPs g2 and g7 cooperatively promote AMPA receptor
expression in cerebellum, and g7 also promotes expression in glia
(Yamazaki et al., 2010). The primary AMPA receptor found in the
hippocampus is a heteromeric combination of GluA1 and 2 subunits,
associated with two g8 auxiliary subunits which modulate gating by
interacting with the GluA2 ligand-binding domain (Herguedas et al.,
2019). The interaction of GluA2 receptors with TARP g8 shifts the
AMPA receptor channel conductance to a higher level (Carrillo et al.,
2019). It will be interesting to test whether the augmentation of
glutamate signal amplitudes by increasing expression or conductance
is a key adaptive mechanism favoring gamma subunit expression
in glioblastoma.
Based on transcriptomic data, the voltage-gated Na+ (NaV) alpha
subunits 1, 2, and 3 appear to be expressed in glioblastoma at the
RNA level. In excitable cells the primary role of NaV channels is to
generate action potentials that can be conducted over distances,
harnessing a regenerative loop fueled by the Na+ gradient. The Na+-
dependent action potential typically links to voltage-gated Ca2+
entry to generate biological work such as the release of
neurotransmitters, secretion of hormones, or contraction of
muscle, for example. The reported absence of measurable action
potentials in identified GBM cells (Venkataramani et al., 2019)
however invites speculation on alternative hypotheses, including
possibilities that NaV protein might not be assembled or functional,
its distribution in plasma membrane might lack a requisite spatial
organization, or shunting of currents through the gap junction-
linked network might render depolarization responses undetectable.Frontiers in Pharmacology | www.frontiersin.org 8In the U87 GBM cell line, the effectiveness of a NaV channel blocker
found to reduce migration and invasiveness was not dependent on
Na+ channel inhibition, not replicated by application of
tetrodotoxin, and was suggested to be due to side effects on RNA
demethylase (Malacrida et al., 2020). In general, NaV channels serve
as a mechanism for the amplification of small excitatory signals into
large amplitude depolarizations, and in principle might contribute a
role in boosting excitatory responses in glioblastoma, but a logical
role for NaV channels in GBM remains to be proposed for testing.
Voltage-gated K+ channels are a large diverse group of channels
that serve to maintain the negative resting membrane potential in
many different types of cells, and to restore the resting voltage
during the repolarization phase of action potential responses in
excitatory cells such as neurons, muscle and sensory cells. Ca2+
dependent K+ channels add the capacity to shape membrane
potential by controlling the amplitude and kinetics of repolarizing
K+ currents in response to both voltage and intracellular Ca2+ levels.
K+ channels identified at moderate transcript levels (Table 1)
include the voltage-gated Kv4.2 (KCND2), an inactivating A-type
channel expressed in brain and heart, and Kv7.2 (KCNQ2), which
alone or with KCNQ3 forms M channels in the central and
peripheral nervous system. M-currents activate and deactivate
slowly, regulating excitability in neurons. Channel closure by Gq-
protein-coupled muscarinic acetylcholine receptors enables
repetitive firing (Brown and Passmore, 2009). The Ca2+-activated
KCa2.2 (KCNN2) and 2.3 (KCNN3), members of the small
conductance class labeled SK, are more sensitive to Ca2+ and less
sensitive to voltage than the big conductance BK channels, and
contribute to hyperpolarized interludes in neurons following bursts
of firing, as reviewed by Kaczmarek and colleagues (2017). In
glioblastoma, a proposed purpose of cation efflux through K+
channels (in parallel with anion efflux though Cl- channels) is to
induce osmotic shrinking, decreasing glioma cell volume to expedite
invasiveness through confined spaces (Olsen et al., 2003).
Alternatively, in the absence of a substantial Cl- leak, K+ currents
would be expected to buffer membrane potential at a negative
voltage, maintaining the driving force for Ca2+ entry (through
pathways including for example, the Ca2+ permeable glutamate
receptors). Relatively high transcript levels in glioblastoma were
indicated for the inward rectifier Kir4.1 (KCNQ2), summarized in
Table 1. This channel is expressed in brain and kidney. In brain
oligodendrocytes, Kir4.1 channels are clustered near nodes in the
myelin, where they are thought to remove accumulations of K+ near
electrically active membranes (Schirmer et al., 2018). Loss of
function of Kir4.1 is associated with axonal degeneration. The
pattern of subcellular localization of the water channel AQP4 in
glial cells coincides with that of the potassium channel Kir4.1,
suggesting a coordination of activities for the spatial buffering of K+
and water homeostasis (Nagelhus et al., 2004; Yool, 2007).SYNAPTIC PROTEINS ENRICHED IN
GLIOBLASTOMA
Since the synapses onto glioblastoma cells are made by neurons,
and reverse synapses have not been observed (VenkataramaniMarch 2020 | Volume 11 | Article 358
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cells would have measureable levels of transcripts for presynaptic
proteins. However, a careful evaluation of the candidate genes
indicates that these proteins might not be exclusively limited to
presynaptic functions. Synaptic proteins in glioblastoma (Table
1) with moderate transcript levels include NSG2 and SYN1.
Neuronal vesicle trafficking associated 2 (NSG2) protein is
abundant in the dendrites and cell bodies of developing
neurons, but its role until recently was unknown. Chander and
colleagues discovered Nsg1 physically interacts with GluA1 and
GluA2 in postsynaptic domains, where it promotes synapse
formation, GluR expression, and synaptic activity (Chander
et al., 2019). Synapsin I (SYN1) is regarded as a reliable
presynaptic marker for immunocytochemistry. In axonal nerve
terminals, it associates with synaptic vesicles to hold them in a
reserve (non-released) pool. Phosphorylation in response to Ca2+
influx causes synapsin I to dissociate, freeing the vesicle for
docking and transmitter release. Immunostaining and northern
analyses have shown SYN1 protein and mRNA can expressed
outside of neural tissues, in liver, epithelia, and cell lines, in
which it is associated with the Golgi complex rather than plasma
membrane, suggesting involvement in protein trafficking (Bustos
et al., 2001). Synapsins have been identified in a variety of non-
neuronal cells (Cesca et al., 2010) including chromaffin cells,
PC12, immature astrocytes, pancreatic beta cells (in which
synapsin I is associated with secretory granules), and in
osteoblasts which are able to trigger glutamate release by
processes mimicking neurotransmission (Bhangu et al., 2001).
It is interesting to note that human glioblastoma cells can release
sufficient glutamate to raise extracellular concentrations up to 600
µM, which promotes GBM cell motility and growth, and causes
excitotoxic cell death and seizures in peritumoral brain tissues
(Corsi et al., 2019). The glutamate release process could be
mediated by entirely by amino acid exchangers; but atypical
neurotransmission-like mechanisms remain to be explored.
High transcript levels in glioblastoma (Table 1) were measured
for SNAP-25, the synaptic vesicle glycoprotein 2A (SV2A), and for
synaptophysin. Synaptosome associated protein 25 (SNAP-25) is
involved in the control of synaptic vesicle exocytosis, and is essential
for synaptic transmission (Jahn et al., 2003). SNAP-25-mediated
effects do not point exclusively to a presynaptic role; it also has been
suggested to govern postsynaptic morphology (Fossati et al., 2015)
and receptor trafficking (Selak et al., 2009; Lau et al., 2010; Jurado
et al., 2013) though some details remain controversial (Antonucci
et al., 2016). SV2A, expressed throughout the brain, is a binding site
for some anti-epileptic drugs such as levetiracetam, and is
differentially associated with GABAergic and glutamatergic
synapses, depending on the brain region, to regulate the balance
of excitatory and inhibitory inputs (Venkatesan et al., 2012; Vanoye-
Carlo and Gomez-Lira, 2019). Knock out of this gene in mice gives
rise to violent spontaneous seizure activity leading to early death.
Although viewed as a marker of neuronal synaptic vesicles,
synaptophysin protein (SYP) was identified in medulloblastoma,
neuroblastoma, and other tumors more than 30 years ago
(Schwechheimer et al., 1987). It is linked to endo- and exocytotic
mechanisms including formation of a fusion pore for the release ofFrontiers in Pharmacology | www.frontiersin.org 9neurotransmitter, though genetic knock out does not result in an
overt phenotype (McMahon et al., 1996). Continuing work has
found synaptophysin immunoreactivity to be a diagnostic and
prognostic tool in a wide array of cancer types, but the functional
role of the protein remains unclear.
Very high transcript levels in glioblastoma (Table 1) were
measured for synaptotagmin-11. Synaptotagmins generally are
associated with evoked release of synaptic and secretory vesicles,
as low affinity Ca2+ sensors that can bind to syntaxin and SNAP-25
(Burgoyne et al., 2019). Synaptotagmin 11 (Syt11), a substrate for
ubiquitinylation by parkin, is one of the risk genes for Parkinson's
disease; overexpression (resulting from parkin dysfunction) leads to
impaired dopamine release, degeneration of dopaminergic neurons,
and associated motor behavioral deficits (Wang et al., 2018a). These
findings indicated a role for synaptotagmin-11 in the inhibition of
endocytosis and vesicle recycling in neurons. Another member of
the synaptotagmin family, Syt3 was shown to interact with GluA2
receptors in postsynaptic membranes, where it enhanced the
endocytosis of receptors in response to Ca2+, generating an
activity-dependent decrease in synaptic strength (Awasthi et al.,
2019). It would be interesting to test the idea that Syt11 in
glioblastoma slows endocytosis of GluA2 receptors, promoting




The specificity of enhanced channel and transporter gene
expressions as markers for GBM can be assessed by comparing
median transcript levels for a protein of interest across a broad
panel of cancer types (Figure 3A) and assessing whether
expression at levels greater than the median correlates with a
poorer prospect of survival (Figure 3B). Aquaporins 1 and 4
(AQP1 and AQP4) are both strongly elevated in GBM; AQP1 is
also upregulated in renal cancer. The high levels of AQP1 and
AQP4 seen in GBM correlate with a poor chance of survival that
is characteristic of the GBM diseases (Figure 2B). Conversely,
the low levels of AQP1 and absence of detectable AQP4
transcripts in stomach and pancreatic cancers do not appear to
offer any protective advantage in terms of survival, and the
higher level of AQP1 in renal cancer does not coincide with a
higher risk of death.
The expression of AQP1 in the leading edges of migrating
cells has been linked to enhanced motility, as documented in
neural crest (McLennan et al., 2020) and various types of cancer
cells including colon cancer, gliomas, breast cancer, and
endothelial cells involved in angiogenic responses (McCoy and
Sontheimer, 2007; Pei et al., 2016a; Nakhjavani et al., 2019;
Tomita et al., 2019). AQP1 is a dual water and ion channel
(Anthony et al., 2000; Yu et al., 2006; Campbell et al., 2012;
Kourghi et al., 2018), which has been suggested to accelerate cell
migration by enabling parallel water and cation entry (Yool et al.,March 2020 | Volume 11 | Article 358
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filopodial extensions needed for forward movement. Inhibition
of either the AQP1 water pores (in each subunit) or the ion
channel (thought to reside in the central pore of the tetramer)
slows migration in AQP1-expressing cancer cell lines (Kourghi
et al., 2016; Pei et al., 2016b), and the inhibition of both shows an
enhanced blocking effect on motility (De Ieso et al., 2019).
Transcript levels for the chloride channel ClC3 are seen across
multiple classes of cancers, with the highest in prostate cancer, fairly
high values in GBM, melanoma and colorectal cancers, and
moderate levels in others. Molecular knockdown of ClC3
channels in glioma cells decreased Cl- efflux, and slowed the
volume decrease associated with DNA condensation in mitosis,
suggesting a role for this conductance in promoting proliferation
(Habela et al., 2008). Block of outwardly rectifying Cl- currents in
U251MG cells with chlorotoxin reduced motility in invasion assays
in vitro and in rat cortical brain slice assays, suggesting glioma cell
motility might be enhanced by a Cl–mediated decrease in cell
volume, facilitating penetration through extracellular matrices
(Soroceanu et al., 1999). Subsequent work showed the site of
action of chlorotoxin in glioma invasion was via the selective
inhibition of matrix metalloprotease-2 (Cao et al., 2013).
Chlorotoxin binds preferentially to cancer cells including gliomasFrontiers in Pharmacology | www.frontiersin.org 10(Lyons et al., 2002), and its promise as a selective histopathological
marker has proven valuable for targeting nanoparticles in situ in
human GBM xenografted mice (Stephen et al., 2019), opening
exciting possibilities for GBM cell-targeted delivery of
chemotherapeutics (Fang et al., 2015).
The sodium proton exchanger NHE1, though a negative
prognostic indicator for GBM, is most strongly expressed in
cancer types such as head and neck, stomach, pancreatic,
urothelial, and comparatively low in GBM. Nonetheless,
increased levels of NHE1 expression found in the lamellipodial
leading edges in primary glioma and GBM cell lines including
U87, U251 and U118 are associated with increased export of
protons, resulting in a more acidic environment and basic
intracellular pH, associated with resistance to temozolomide,
and enhanced tumor progression (Cong et al., 2014).
Other candidates meriting further analysis include gap junction
channels (connexin 26) and bestrophin. Connexin 26, Cx30 and
Cx43 are characteristic components of the majority of gap junctions
between astrocytes in the rat central nervous system (Rash et al.,
2001). Bestrophin Ca2+-activated anion channels are permeable to
chloride as well as large organic anions such as glumate and GABA;
they are expressed throughout the brain and in the retinal pigment
epithelium of the eye, in which inherited mutations are associatedA B
FIGURE 3 | Comparison of transcript levels across different cancers. (A) Heat map comparison of median transcript levels (FPMK, color bars) across a panel of
different cancers. (B) Heat map comparison of patient survival at 3 years (%, color bars) across a panel of different cancers. Results were calculated from TCGA data
available in the Human Protein Atlas. TCGA, The Cancer Genome Atlas.March 2020 | Volume 11 | Article 358
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of these channels in GBM remain to be determined.PROGNOSTIC VALUE IN EVALUATING
SETS OF SIGNALING PROTEINS
The GBM Bio Discovery portal provides an interface for evaluating
defined sets of multiple genes as prognostic indicators, drawing on
the Human Protein Altas TCGA transcriptomics database. For the
analysis here, clusters of genes were created from the GBM-enriched
genes summarized in Table 1 that had strong reliability scores (i.e.,
links to GBM based on multiple lines of evidence including
immunocytochemistry, protein and RNA analyses, as denoted by
“pathological evidence” scores of 1.0). The three clusters created
were ionotropic neurotransmiter receptors, ion channels, and
synaptic proteins (Figure 4). Data are presented as heatmaps
(above), and as Kaplan Meier survival curves (below) for each
cluster. Each column in the heat map represents data from a single
GBM patient, and illustrates the different transcript levels measured
for the genes in the cluster, presented as Z-scores relative to the
average transcript level across the GBM sample population.
Subtypes of glioblastoma assigned per patient are depicted by a
color key (top row). Column order in the heat map columns reflects
overall transcript levels, with predominantly low (blue) on the left
side of the heat map, ranging to high (red) on the right side.
The subtype categories (neural, proneural, mesenchymal, and
classical) serve as a useful tool for TCGA data analysis but do not
reflect a consensus opinion; evidence for the neural classification has
been questioned (Behnan et al., 2019) leaving support for three
subtypes only. Limitations of the TCGA database include the fact
that many of the samples analyzed were taken from single random
sites in the tumor bulk, not capturing the inherent heterogeneity of
subtypes across different regions within the tumor (Puchalski et al.,
2018). However, biological relevance for the classification scheme
has been supported by similarities in expression profiles of glioma
cells with those of brain cell populations, prompting the idea that a
common source for the gliomas might be pleuripotent neuronal
stem cells of adult brain, which become glioblastoma stem cells and
differentiate into subtypes based on environmental and genetic
factors. Proneural cells show an oligodendrocyte progenitor cell-
like signature, and classical and mesenchymal subtypes reflect
astrocyte-like lineages (Verhaak and Valk, 2010; Alcantara
Llaguno et al., 2015).
For the Ionotropic receptors (Figure 4A) and Ion channels
(Figure 4B) clusters, the samples with predominantly high levels of
expression (right side) correlated most frequently with GBM
subtypes diagnosed as proneural in character. For the Synaptic
proteins cluster (Figure 4C), the high expression patterns correlated
with both proneural and neural subtypes of GBM. The branched
tree (left side of the heat map) summarizes the degree of covariance
in transcript levels for genes within the cluster. The survival plots in
each cluster demonstrated that the prognostic impact of expression
of a set of genes was stronger than that of any individual gene alone,
as indicated by Hazard Ratio (HR) scores nearing as high as four for
clusters (i.e., a 4-fold increase in chance of death in 3 years forFrontiers in Pharmacology | www.frontiersin.org 11transcript levels > median), as compared with hazard ratios close to
1.0 (ranging mainly 0.8 to 1.2) when evaluated for individual genes.
A comparable analysis of genes in the ‘Other channels and
transporters' cluster (Figure 5) based on Table 1 (not limited to
pathological evidence scores of 1.0) shows that patterns of high
transcript levels in this group correlated most strongly with the
classical and proneural subtypes of GBM, with hazard ratios of
2.4 to 2.5 determined from survival curves.
Transcriptomic data analyses indicated that the proneural
subtype is consistently correlated with patterns of transcript levels
across several clusters of membrane signaling proteins associated
with GBM, and illustrate the point that calculations of hazard ratios
for related groups of genes in GBM could have a stronger prognostic
significance with respect to evaluating patient survival time than
predictions based on expression levels of single genes alone. This
insight at the genomic level is likely to be meaningful from a
functional point of view as well. A major limitation that must be
kept in mind in these analyses is that the tumor biopsy samples used
for generating the RNAseq database were taken from random
locations in the tumor, and thus are unlikely to capture the full
heterogeneity and range of cell phenotypes within the tumor mass,
complicating determination of correlations with patient survival
and transcript prognostic value. Nonetheless, the transcriptomic
analyses highlight the concept that cellular signaling is carried out
by sets of proteins with partial overlap in functional properties,
providing cells with capacity for compensation following the loss of
a given signaling component. Therapeutic strategies aimed at
modulating multiple proteins within a class, and multiple targets
across classes, might prove to be more effective in realizing a
clinically relevant outcome. A key point is that an ideal treatment,
tailored to a given cancer, would incorporate multiple
pharmacological agents targeted across a set of key proteins, each
administered at low doses to reduce the severity of side effects, but
achieving potency by a synergistic complementation. In this regard,
it will be of interest to screen herbal medicinal extracts comprising
naturally complex combinations of chemical components, for effects
on a panel of different classes of signaling proteins for potentially
synergistic interactions.NATURAL PLANT PRODUCTS AS
SOURCES OF THERAPEUTIC AGENTS
The current therapies for glioblastoma involving temozolomide
chemotherapy, radiation, and surgical resection yield only
limited improvements in survival periods. New drugs that
induce fewer side effects and lead to more favorable prognoses
are needed. Plant extracts have since ancient times been used
traditionally as medicines in Egypt, China, India, Greece, and
other countries. Some of the first written records on the
medicinal uses of plants date back to 2600 BC. The plant
kingdom comprises nearly 250,000 plant species of which only
around 10% have been screened thus far for different diseases.
Medicinal herbs found by experience to be valuable for treating
diseases and ailments have served as original sources for many
clinical compounds in the current therapeutic armamentarium.March 2020 | Volume 11 | Article 358
Yool and Ramesh Combined Targets for Glioblastoma TherapyThe National Cancer Institute (USA) has screened 35,000 plant
samples (114,000 extracts) from 20 countries for anti-cancer
activity (Developmental Therapeutics Program, NIH, USA).
Approximately 60% of the clinically approved anti-cancer
drugs available commercially are derived from medicinal plantsFrontiers in Pharmacology | www.frontiersin.org 12(Khan, 2014). Many studies have considered compounds as
effective potential anticancer treatments if they arrest the cell
cycle or trigger apoptosis (reducing proliferation), impair
angiogenesis (reducing metabolic supply), or decrease the
expression of matrix metalloproteinases (impairing invasion)A
B
C
FIGURE 4 | Evaluation of expression patterns and additional prognostic information available in analyzing sets of related signaling genes, for ionotropic
neurotransmitter receptors (A), ion channels (B), and synaptic proteins (C) enriched in glioblastoma. Data were analyzed using the GBM Bio Discovery Portal, a
resource for user-specified interrogation of The Cancer Genome Atlas (TCGA) database, for glioblastoma multiforme categorized by molecular subtype (Verhaak
et al., 2010). GBM, glioblastoma multiforme.March 2020 | Volume 11 | Article 358
Yool and Ramesh Combined Targets for Glioblastoma Therapyas reviewed by Park, Erices, and colleagues (Park et al., 2017;
Erices et al., 2018). Ability to cross the blood brain barrier would
facilitate drug delivery to the tumors.
Natural plant products tested in glioblastoma including
flavonoids, terpenoids, polyphenols, epigallocatechin gallate,
quinones, saponins, and others (Table 2), have been assayed
mainly in glioblastoma cell lines, as well as xenografts in mice. A
diverse set of plant products are effective in slowing proliferation
and migration, and increasing cell death. The molecular
mechanisms underpinning the effect of these compounds
include decreased expression of angiogenic factors (VEGF and
TGF-b1), disruption of signaling pathways (PI3K/AKT/mTOR,
RAF-MEK-ERL, TLR4, IL-6 mediated JAK/STAT3, and Rho/
ROCK), impaired mitosis (cell cycle arrest at G2/M phase),
decreased expression of proliferation-associated genes (PCNA
and cyclin D1), enhancement of apoptosis by increased Caspases
(CASP 3, 9) and PARP 1 cleavage activities, decreased anti-
apoptotic protein (Bcl-2) expression, downregulation of the
activity of matrix metalloproteinases (MMP 2,9,14,16), and
inhibition of actin assembly (see references in Table 2).
The limited number of natural plant compounds identified as
inhibitors of motility in glioblastoma (Table 2) included bittersweet
(Celastrus orbiculatus), curcubitacin B (Trichosanthes kirilowii),
OLE (Olea europaea leaf), paeoniflorin (Radix paeoniase alba),
resveratrol (red wine and other sources), and withaferin A
(Withania somnifera); however, it is important to note that
potential anti-motility effects of other glioma-active plant
preparations in Table 2 are not excluded, but remain to be
evaluated. A useful starting point is to survey whether any of the
motility-blocking herbal compounds have published effects on ionFrontiers in Pharmacology | www.frontiersin.org 13channels or ionotropic receptors. Evidence is limited in this under-
researched field, but available publications suggest possible links.
For example, celangulin I isolated from bittersweet activated high-
voltage activated L-type Ca2+ channels in insect neurons, consistent
with excitoxicity and insecticidal activity (Li et al., 2016b).
Cucurbitacin IIa decreased the expression of glutamate receptors
GluN2B (NMDA) and GluA1 (AMPA), and increased GABAAa2
expression in mouse brain amygdala (Zhou et al., 2017). OLE from
Olea inhibited L-type Ca2+ currents in rat cardiac cells (Scheffler
et al., 2008), and reduced L-type Ca2+ channel RNA levels in rat
spinal cord (Zare et al., 2012). Oleuropein from Olea caused dose-
dependent increases in intracellular Ca2+ in mesothelioma cells,
suggested to bemediated by activation of low-threshold T-type Ca2+
channels (Marchetti et al., 2015). An analgesic action of paeoniflorin
was suggested to be mediated by activating adenosine A1 receptors
and reducing glutamate release in rat pain sensory fibers (Zhang
et al., 2009). Resveratrol has been found alter activity in an array of
ion channel classes, including the inhibition of Ca2+ channels
involved in pain perception pathways in mice, consistent with an
anti-nociceptive effect of systemic treatment (Pan et al., 2017),
inhibition of cardiac L-type Ca2+ currents in rat ventricular
myocytes (Zhang et al., 2006), and activation of T-type Ca2+
channels in a mesothelioma cell line (Marchetti et al., 2016),
providing an interesting parallel with the effects of Olea extracts
listed above. Resveratrol activated defined subtypes of GABAA
receptors containing a1 subunits, expressed in Xenopus oocytes
(Groundwater et al., 2015), and blocked the calcium-dependent K+
channel, KCa3.1, heterologously expressed in 3T3 fibroblasts
(Olivan-Viguera et al., 2013). Withania extract activated
mammalian brain GABAA and GABArho receptors recorded byFIGURE 5 | Evaluation of expression patterns for additional classes of channels enriched in glioblastoma. Data were analyzed using the GBM Bio Discovery Portal.
GBM, glioblastoma multiforme.March 2020 | Volume 11 | Article 358
TABLE 2 | Summary of alternative medicinal compounds and extracts reported to affect proliferation, viability, and/or motility of glioblastoma and malignant brain tumor cells.
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Frontiers in Pharmacology | www.frontiersin.org 20voltage clamp in the Xenopus expression system, evoking currents
comparable to those induced by the native neurotransmittter;
however, responses were not activated by the isolated components
withaferin A and withanolide A, suggesting other active agents are
present in the extract (Candelario et al., 2015). These observations
point to an important gap in knowledge regarding the ion channel
and receptor modulatory effects of anti-cancer medicinal
herb extracts.
It is interesting to note that some compounds such as curcumin
[1.25 µg/ml] (Yin et al., 2014), OLE extract [1 mg/ml] (Tezcan et al.,
2017a), resveratrol [10 µM] (Yuan et al., 2012) and quercetin [30
µmol/L] (Sang et al., 2014) when tested in combination with
temozolomide have been effective in increasing survival in animal
models, overcoming temozolomide resistance by increasing ROS
production, disrupting AKT/mTOR signaling, reducing MGMT
gene expression, suppressing Hsp27 protein expression, and
downregulating the expression of MMP-2 and -9. The plant
derived compounds are effective in low doses and intriguingly the
effective concentration of temozolomide required in combination is
also reduced (50–100 µM) leading to more effective treatments with
fewer side effects. Thus, natural products from traditional medicinal
plants could prove useful in combination with other plant products
or chemotherapy drugs, as a new way forward in treating
glioblastoma tumors and improving prognoses, alone and in
combination with front-line chemotherapeutic agents.COMBINING MODULATORS FOR
MULTIPLE TARGETS TO INCREASE
SELECTIVITY AND POTENCY OF
TREATMENTS FOR GLIOBLASTOMA
Selected sets of membrane signaling proteins that are upregulated in
glioblastoma might be added to the matrix of markers supporting
diagnosis and targeted intervention. Moving from bench to bedside
is challenging; many failures have resulted from approaches focused
on single targets and single agents as therapies. Combinations of
agents offer potential to focus treatmentsmore precisely on a class of
cells of interest, based on unique signature profiles reflecting
expression of multiple key proteins from more than one essential
pathway. However even combinations of approaches have not yet
achieved the desired endpoints.
The standard current therapy for GBM does use a combined
approach, employing radiotherapy, temozolomide chemotherapy
and surgical resection. Studies have explored possible benefits of
layering additional agents onto this standard therapy regime with
the aim of further extending survival. Some logical pharmacological
candidates such as gefitinib (an inhibitor of the EGF receptor) or
bevacizumab (an inhibitor of angiogenesis) added to the standard
therapy have not met the aims for improved overall survival
(Okonogi et al., 2015).
With a diverse types of GBM-enriched proteins all appearing to
point to a major role for glutamate signaling in glioblastoma,
glutamate receptors are a clear target of interest for potential
therapies, but have proven elusive thus far. Glutamate driven Ca2+
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Yool and Ramesh Combined Targets for Glioblastoma Therapyglutamate in the local environment causes neuronal loss and further
recruits tumor-associated microglia which produce growth factors
enhancing tumor cell survival (Corsi et al., 2019). AMPA receptors
are associated with integrin, and could contribute localized signaling
at cytoskeletal anchor points in focal adhesion complexes (Piao et al.,
2009) which might be key in invasive motility. A non-competitive
antagonist of AMPA receptors, talampanel (also known as GYKI
53773 or LY300164) was found to increase the median survival of
patients with GBM (20.3 months versus 14.6 months) in a cohort
study of 60 patients (Grossman et al., 2009). Despite promise in Phase
II, it has not been validated further and might be limited by a short
half-life of 3 h (Langan et al., 2003). This agent, a derivative of
benzodiazepine, also blocks kainate receptors (Donevan et al., 1994).
Targeting the AMPA glutamate receptors would seem to be a
compelling approach. However, the predominant role of AMPA
receptors in fast excitatory signaling throughout the central nervous
system raises a challenge on how to target inhibitors selectively to
cancer cells while maintaining tolerability. Most AMPA receptor
antagonists tested thus far have proven unsuitable due to side effects
and pharmacokinetics, in contrast to effectiveness in preclinical
animal models (Lee et al., 2015). The natural extracts in traditional
medicines that have been found to be effective might serendipitously
include agents which modulate more than one of the classes of
signaling molecules highlighted in this review, that are enriched in
glioblastoma and could be important contributors to the
pathological process. New approaches will be likely to exploit
evidence-based combinations of selected agents, each at low
doses, along with tools for cancer-selective targeting to GBM cells,Frontiers in Pharmacology | www.frontiersin.org 21to engineer new and potent therapeutic strategies for meeting the
medical challenge of treating glioblastoma.DATA AVAILABILITY STATEMENT
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